IFNB1 and COVID-19: The pharmacological treatment administered during the ICU stay was primarily tocilizumab (58.7%) and glucocorticoids (98.0%), followed by other drugs employed exclusively during the first wave of COVID-19, such as hydroxychloroquine (21.2%), lopinavir-ritonavir (19.2%) and interferon beta (17.3%).